FDA approves Viatris' low-dose estrogen weekly patch?

9.0 pts (24h)Health & MedicineWeekly2d

PolymarketVerificar disponibilidadeSem KYC2% de taxaDados de resolução verificadosRazoavelmente calibrado

Probabilidade implícita atual

Sim 63%-0.1pt

Qualidade do mercado

32 / 100

Baixa qualidade

Volume 24h

0 €

Liquidez

96,9 €

Baixa liquidez

Compra / Venda

39.0% / 87.0%

Spread

48.0 pt

Spread amplo

Variação 7d

+8.0 pts

Dados do mercado

Atualizado há 17 minutos

1/07/26, 6:1430/07/26, 17:59

Tendências

Resultado24hProbabilidade

Apenas fundos simulados, sem dinheiro realIsto não é aconselhamento financeiro

Resultado escolhido

Yes63%

Aposta (USDT)

Regras

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Tendência de volume

2 de jul.20d de dados21 de jul.

Mercados Relacionados

Will AbbVie Q2 Global Skyrizi net revenues be above __?

0 €

$19B: 4%

POLYMARKET

What price will Bitcoin hit July 27-August 2?

16,1 mil €

↓ 62,000: 64%

POLYMARKET

Chipotle chicken burrito price in July 2026

8 mil €

At least $9.76: 96%

KALSHI

Price of NVIDIA B200 compute by Jul 31, 2026?

4,2 mil €

Above $3.96: 99%

KALSHI

Price of NVIDIA H100 SXM compute by Jul 31, 2026?

4,1 mil €

Above $2.71: 50%

KALSHI

What price will Ethereum hit July 27-August 2?

2,3 mil €

↓ 1,900: 100%

POLYMARKET

Ativos nestes tópicos

EthereumETH$1,881.74-3.63%

BitcoinBTC$63,342.25-3.02%

SolanaSOL$73.21-4.19%

XRPXRP$1.06-4.50%

BNBBNB$566.49-1.25%

DogecoinDOGE$0.0702-3.70%

Notícias Relacionadas

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regras

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

FDA approves Viatris' low-dose estrogen weekly patch?

9.0 pts (24h)Health & MedicineWeekly2d

PolymarketVerificar disponibilidadeSem KYC2% de taxaDados de resolução verificadosRazoavelmente calibrado

Probabilidade implícita atual

Sim 63%-0.1pt

Qualidade do mercado

32 / 100

Baixa qualidade

Volume 24h

0 €

Liquidez

96,9 €

Baixa liquidez

Compra / Venda

39.0% / 87.0%

Spread

48.0 pt

Spread amplo

Variação 7d

+8.0 pts

Dados do mercado

Atualizado há 17 minutos

1/07/26, 6:1430/07/26, 17:59

Tendências

Resultado24hProbabilidade

Apenas fundos simulados, sem dinheiro realIsto não é aconselhamento financeiro

Resultado escolhido

Yes63%

Aposta (USDT)

Regras

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Tendência de volume

2 de jul.20d de dados21 de jul.

Mercados Relacionados

Will AbbVie Q2 Global Skyrizi net revenues be above __?

0 €

$19B: 4%

POLYMARKET

What price will Bitcoin hit July 27-August 2?

16,1 mil €

↓ 62,000: 64%

POLYMARKET

Chipotle chicken burrito price in July 2026

8 mil €

At least $9.76: 96%

KALSHI

Price of NVIDIA B200 compute by Jul 31, 2026?

4,2 mil €

Above $3.96: 99%

KALSHI

Price of NVIDIA H100 SXM compute by Jul 31, 2026?

4,1 mil €

Above $2.71: 50%

KALSHI

What price will Ethereum hit July 27-August 2?

2,3 mil €

↓ 1,900: 100%

POLYMARKET

Ativos nestes tópicos

EthereumETH$1,881.74-3.63%

BitcoinBTC$63,342.25-3.02%

SolanaSOL$73.21-4.19%

XRPXRP$1.06-4.50%

BNBBNB$566.49-1.25%

DogecoinDOGE$0.0702-3.70%

Notícias Relacionadas

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regras

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs